Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of vaccines in China and internationally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. The company also develops rabies vaccine which is in new drug approval stage; influenza vaccine which is in new drug application stage; recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage; and 13-valent pneumococcal polysaccharide conjugate, varicella, and meningococcal A, C, Y and W-135 conjugate vaccines which are in Phase I clinical stage. In addition, it is involved in the development of high-dose influenzae vaccine which is in CT approval stage; and vaccines in pre-clinical study stage, including 20-valent pneumococcal polysaccharide conjugate, recombinant zoster, multivalent HFMD, serogroup B meningococcal outer membrane vesicle, and rabies monoclonal antibody. The company was formerly known as Liaoning Chengda Biological Technology Limited Company and changed its name to Liaoning Chengda Biotechnology Co., Ltd. in November 2010. Liaoning Chengda Biotechnology Co., Ltd. was incorporated in 2002 and is headquartered in Shenyang, China. The company operates as a subsidiary of Liaoning Cheng Da Co., Ltd.